Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 3Phase NA 1

Status

Unknown 2Suspended 1

Sponsor Class

OTHER 20INDUSTRY 10NETWORK 4NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Central Nervous System Neoplasms 2Glioblastoma 1

Interventions

Specimen Handling 180Cyclophosphamide 161Magnetic Resonance Spectroscopy 153Biopsy 128Radiotherapy 109Cisplatin 109Bevacizumab 107Carboplatin 101Doxorubicin 96Paclitaxel 94Etoposide 87Filgrastim 81aldesleukin 78Gemcitabine 73Vincristine 72Fluorouracil 72Leucovorin 62fludarabine phosphate 58Docetaxel 58Bortezomib 54Sorafenib 53Cytarabine 51Methotrexate 50Taxes 49Immunoglobulin G 49Disulfides 49Rituximab 48Oxaliplatin 48sargramostim 47Prednisone 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × NIH × Lomustine × Clear all
NCT06325683 2026-05-26

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Suspended
184 enrolled
CNS

Glioblastoma

NCT00276666 2013-09-17

Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Metastatic Medulloblastoma Who Have Undergone Surgery

National Cancer Institute (NCI)

Phase 2 Unknown
29 enrolled
CNS

Central Nervous System Neoplasms

NCT00274911 2013-08-02

Radiation Therapy Followed By Combination Chemotherapy in Treating Young Patients With Supratentorial Primitive Neuroectodermal Tumors

National Cancer Institute (NCI)

Phase 2 Unknown
30 enrolled
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡